ACXP Overview

Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. It develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme.

Wall Street analysts forecast ACXP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACXP is30.50 USD with a low forecast of 30.00 USD and a high forecast of 31.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Acurx Pharmaceuticals Inc revenue for the last quarter amounts to -1.72M USD, decreased -20.16

Acurx Pharmaceuticals Inc. EPS for the last quarter amounts to USD, decreased

Acurx Pharmaceuticals Inc (ACXP) has 4 emplpoyees as of May 30 2026.

Today ACXP has the market capitalization of 8.51M USD.